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CC BY-NC-ND license (http://creativeBackground/purpose: Diffuse panbronchiolitis (DPB) is a rare clinicopathological entity. To
date, no cohort study of DPB has been conducted in Taiwan. Erythromycin treatment improves
the clinical outcome of DPB; however, whether relapse will occur or not is unclear. Herein, we
report the first retrospective cohort of DPB patients in one medical center in Taiwan, including
their clinical presentation and outcomes of erythromycin treatment.
Methods: The study comprised a retrospective cohort analysis of 27 patients with a confirmed
diagnosis of DPB. Clinical, radiological, and laboratory parameters were analyzed, and the
course and outcome of erythromycin treatment were examined.
Results: The mean age at symptom onset was 56.6  18.5 years, and the time between symp-
tom onset and a correct diagnosis was 4.3  4.2 years. The percentages of patients with cen-
trilobular micronodules on chest computed tomography, obstructive ventilator impairment
with hypoxemia, and an elevated cold agglutinin titer were 72%, 37%, and 78%, respectively.
After erythromycin treatment, 22 of the 27 (81.5%) patients showed clinical improvement,
of whom six suffered a relapse. Four of these six patients clinically improved after a second
course of erythromycin treatment.
Conclusion: Erythromycin therapy was suitable for DPB in our experience. In this study cohort,
27% experienced a relapse, of which two-thirds of the patients improved after a second course
of erythromycin treatment.
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open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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Figure 1 Flowchart for selecting the cohort of DPB patients.
CHA Z cold agglutinin; DPB Z diffuse panbronchiolitis.
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Diffuse panbronchiolitis (DPB) is a chronic inflammatory
disease of unknown etiology that affects the distal airways,
and predominantly the transition zone between the respi-
ratory bronchioles and alveoli.1 If left untreated, it can
progress to bronchiectasis, respiratory failure, and death.2
The prognosis of DPB is poor, and the reported 10-year
survival rate was only 33.2% in 1983. Since long-term
treatment with erythromycin was introduced in 1984, the
10-year survival rate has improved to 90%.3,4 However, the
incidence of relapse after completing a course of erythro-
mycin treatment and the response rate to a second course
of treatment remain unclear. Nevertheless, an early and
correct diagnosis followed by immediate erythromycin
treatment is most important for DPB patients.
DPB was first described by Yamanaka et al2 in 1969 in
Japan as a suppurative and obstructive airway disease that
coexists with sinusitis. DPB was subsequently recognized in
other parts of Asia, including Korea and China 5,6; however,
the clinical presentations appear to be slightly different
between these areas. To date, only a few cases of DPB have
been reported in Western countries.7,8 The first case of DPB
in Taiwan was reported in 1991,9 and to the best of our
knowledge, only seven case reports and one article
including a total of 11 patients with findings on plain chest
film and high-resolution computed tomography (HRCT) have
been published in Taiwan.10e17 The scarcity of published
data raises the concern that most clinicians may be unfa-
miliar with DPB, and that it could be underdiagnosed in
Taiwan.
It is unknown whether the clinical presentations and
response to erythromycin treatment in Taiwanese patients
are similar to those observed in Japanese patients. Hence,
the aim of this study was to investigate the clinical profiles
and responses to erythromycin treatment in 27 Taiwanese
DPB patients, including the relapse rate and the response to
a second course of erythromycin treatment.Methods
Patients
This retrospective study was approved by the local Insti-
tutional Review Board (IRB) of Chang Gung Memorial Hos-
pital (IRB approval number 103-3795C).
From January 1, 2002, to January 1, 2014, 645 patients
who received the serum cold hemagglutinin (CHA) test were
screened retrospectively. We sequentially excluded pa-
tients who were younger than 18 years and those who
received the CHA test for a reason other than suspected
DPB (Figure 1). We further excluded patients who did not
meet the following diagnostic criteria of DPB:
(1) persistent cough, sputum, and exertional dyspnea
(2) History or current symptoms of chronic sinusitis
(3) Bilateral, diffuse, small nodular shadows on a plain
chest radiograph or centrilobular micronodules on
chest computed tomography (CT) images
(4) Coarse crackles(5) The ratio of forced expiratory volume in 1 second
(FEV1) to forced vital capacity (FVC) (FEV1/
FVC) < 70% and partial pressure of oxygen
(PaO2) < 80 mmHg (10.64 kPa)
(6) CHA titer of  64
These criteria were proposed by a working group of the
Ministry of Health and Welfare of Japan.18 All patients
enrolled for final analysis should fulfill the first three
criteria and at least two of the remaining criteria. Two of
our patients were also diagnosed to have DPB by histo-
pathological examination.
The medical records and radiological reports were evalu-
ated by two pulmonologists to confirm the accuracy of the
extracted information, which included demographic data,
arterial blood gas analysis, blood CHA test, pulmonary func-
tion test, radiological findings, and pathological findings.
The duration of erythromycin treatment was calculated
according to the medical records. The patient’s response to
erythromycin treatment (failure, clinical improvement, or
radiological improvement) and the recurrence of DPB (wors-
ening of clinical symptomsand theneed for a secondcourse of
erythromycin treatment, as judged by the physician) were
also documented according to the medical records.
Statistical analysis
Data were analyzed using Predictive Analytics SoftWare
Statistics 18 (SPSS Inc., Chicago, IL, USA). Continuous data
were presented as mean  standard deviation, and cate-
gorical data were presented as number and percentage.
The paired t test was used to compare pulmonary test re-
sults before and after erythromycin treatment. All tests
were two tailed, and a p value < 0.05 was considered to be
statistically significant.
Results
Demographic data
Twenty-seven patients were enrolled in the final analysis,
with a male-to-female ratio of 1.08. The mean age at
symptom onset was 56.6  18.5 years, and the mean age at
diagnosis of DPB was 60.5  17.1 years (Table 1). The
Table 1 Baseline characteristics of patients with diffuse
panbronchiolitis (n Z 27).
Characteristic Value
Age at presentation (y) 56.6  18.5
Age of diagnosis (y) 60.5  17.1
Time between symptoms
and diagnosis (y)
4.3  4.2
Male patients 52
Body mass index (kg/m2) 22.4  4.3
Smoking history 22
Had been diagnosed with asthma 44
Had been diagnosed with COPD 37
Chronic sinusitis 100
Productive cough 100
Hemoptysis 30
Body weight loss 19
Exertional dyspnea 30
Crackle 100
Wheezing 59
FEV1/FVC (%)a 66.7  13.1
FEV1 (% predicted)a 45.2  18.9
FVC (% predicted)a 49.4  15.5
FEF25e75% (% predicted)a 38.9  27.6
PaO2 (mmHg)
b 81  23
PaCO2 (mmHg)
b 44  17
Values given as mean  standard deviation or percentages.
COPD Z chronic obstructive pulmonary disease;
FEF25e75% Z forced inspiratory flow at 25e75% of the
pulmonary volume; FEV1 Z forced expiratory volume in one
second; FVC Z forced vital capacity; PaCO2 Z arterial oxygen
carbon dioxide tension; PaO2 Z arterial oxygen tension.
a Data from 25 of 27 patients.
b Data from 19 of 27 patients.
Table 2 Percentages of patients fulfilling each criteriona
(n Z 27).
Criterion Percentage
1. Persistent cough, sputum,
and exertional dyspnea
100
2. History of chronic paranasal sinusitis 100
3. Bilateral, diffuse, small
nodular shadows on a plain
chest radiography film or centrilobular
micronodules on chest computed
tomography (CT) images
100
3.1. Centrilobular micronodules on
chest CT imageb
72
3.2. Bilateral diffuse small nodules
on a plain chest film
96
4. Coarse crackles 100
5. FEV1/FVC < 70% and PaO2 < 80 mmHg 37
5.1. Patient with PaO2 < 80 mmHg
b 58
5.2. Patient with FEV1/FVC < 0.7c 64
6. Titer of cold agglutinin  64 78
FEV1 Z forced expiratory volume in 1 second; FVC Z forced
vital capacity; PaO2 Z arterial oxygen tension.
a Criteria are taken from a working group of the Ministry of
Health and Welfare of Japan.18 Cases definitely established
should fulfill Criteria 1, 2, and 3, along with at least two of
Criteria 4, 5, and 6.
b Data from 25 of 27 patients.
c Data from 19 of 27 patients.
878 M.-C. Chuang et al.interval between the first clinic visit and the correct diag-
nosis was 4.3  4.2 years. Surprisingly, only 22% of the
patients had a history of smoking, however, 37% were
diagnosed and treated for chronic obstructive pulmonary
disease. In addition, 44% of the patients were diagnosed
and treated for asthma.Clinical manifestations
All of the patients presented with chronic sinusitis, chronic
cough, and copious sputum production. Other common
presentations included hemoptysis (30%), exertional dys-
pnea (30%), and body weight loss (15%). On physical ex-
amination, all of the patients were found to have end-
inspiratory crackles, and 59% also had wheezing.Laboratory findings
Arterial blood gas analysis on room air was available for 19
of the 27 (70%) patients. The PaO2 and partial pressure of
carbon dioxide (PaCO2) values are shown in Table 1. Mild
hypercapnia without hypoxemia was noted in our cohort.
All of the patients received a serum CHA test. According
to the definition of our laboratory, 90% of our patients had a
positive result (CHA titer  16). However, only 78% of ourpatients met the diagnostic criteria of DPB (CHA titer  64;
Table 2).Pulmonary function
Pulmonary function tests were available for 25 of the 27
(93%) patients. The FEV1/FVC, FEV1, FVC, and forced
expiratory flow 25e70% (FEF25e75%) values are presented
in Table 1. Although the mean FEV1/FVC was < 70%, nine of
the 25 (36%) patients demonstrated pure restrictive venti-
latory impairment. In addition, only 22 of the 25 (88%)
patients had narrowing of the small airway as defined by
FEF25e75% < 65% of predicted values.Radiological manifestations
Twenty-six of the 27 (96%) patients had a bilateral, diffuse,
small nodule pattern on plain chest film. Twenty-five of the
27 (93%) patients underwent chest CT around the time of
their diagnosis, and they were scanned in the supine posi-
tion (scan thickness 1 mm and slice interval 10 mm) at the
end of inspiration. Only 72% of these patients had small
nodules distributed in a centrilobular fashion and con-
nected to small linear opacities, the so-called tree-in-bud
pattern, which was described previously as CT classification
type II by Odaka et al.19 Peripheral air trapping, emphy-
sema, interstitial change, and bronchiectasis were also
observed in some of the patients.
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To further confirm the diagnosis, two of our patients un-
derwent open lung biopsy. Both of them showed the typical
pathological changes of DPB including diffuse, bilateral
chronic airway inflammation with some centrilobular
chronic interstitial inflammation; the classic feature of
foam cells in the walls of respiratory bronchioles, alveolar
ducts, and alveoli; intraluminal acute inflammation;
follicular bronchiolitis; bronchiectasis; organizing pneu-
monia; and postobstructive lipoid pneumonia.
Diagnostic criteria
The percentages of the patients fulfilling each diagnostic
criterion are summarized in Table 2. As mentioned, all
patients had typical symptoms, a history of chronic para-
nasal sinusitis, crackling sounds while breathing, and
typical imaging findings. However, only 30% of the patients
complained of exertional dyspnea (Table 1). Surprisingly,
eight patients had bilateral, diffuse, small nodular shadows
on plain chest radiography but did not have typical cen-
trilobular micronodules on chest CT. Only 37% of the pa-
tients had both FEV1/FVC < 70% and PaO2 < 80 mmHg, and
78% of the patients had a CHA titer of  64%.
Outcome of erythromycin treatment
According to current guidelines,20,31 all patients were
treated with erythromycin (400e600 mg/d orally) since
their DPB diagnosis. Table 3 presents the outcomes of
erythromycin treatment in our DPB patients. After treat-
ment, 22 of the 27 patients (82%) showed improvement
clinically; however, only 56% of the patients demonstrated
improvements in radiological findings. Of the five patients
who did not respond to erythromycin treatment, four pro-
gressed and needed long-term oxygen therapy during the
observation period, and two of these patients eventually
became ventilator dependent. Two of the 27 patients died
during the follow-up period: one due to a head injury and
the other due to pneumonia-related respiratory failure.
Sixteen of the 27 (59%) patients received pulmonary
function tests after completing erythromycin treatment.
Figure 2 shows the comparisons of pulmonary function testsTable 3 Outcomes of diffuse panbronchiolitis patients
after erythromycin treatment (n Z 27).
Value
Follow-up period (mo) 27.7  16.4
Treatment duration (mo) 7.9  7.7
Clinical improvement 22 (82)
Radiological improvement 15 (56)
Both clinical and radiological improvement 13 (48)
Recurrence 6 (22)
Long-term oxygen use 4 (15)
Ventilator dependent 2 (7)
Mortality 2 (7)
Values given as mean  standard deviation or n (%).before and after treatment. After erythromycin treatment,
significant improvements in FEV1 (before vs. after,
40.3  15.8% of predicted vs. 50.1  23.8% of predicted;
p < 0.05) and FVC (before vs. after, 45.2  15.2% of pre-
dicted vs. 57.6  21.7% of predicted; p < 0.05) were noted.
However, the improvement in FEF25e75% was not statisti-
cally significant (before vs. after, 31.9  19.5% of predicted
vs. 37.1  25.7% of predicted; p Z 0.341). Overall, 75%,
75%, and 56% of the patients had improvements in FVC,
FEV1, and FEF25e75%, respectively.
Six of the 22 patients (27%) experienced recurrence of
clinical symptoms after completing erythromycin treat-
ment. The treatment duration of these patients was
7.5  8.6 months, and the symptom-free interval was
19.9  12.7 months. The second treatment course of
erythromycin had a duration of 7.4  7.4 months. Four of
the six (67%) patients achieved clinical improvement again.
One patient was lost to follow up after receiving 1 month of
treatment, and one patient failed to respond to the second
course of erythromycin treatment and became ventilator
dependent (Table 4).Discussion
Only a few studies about DPB in Taiwan have been pub-
lished (Table 5)9e16, and this study is the first and largest
retrospective cohort study in Taiwan to date. We investi-
gated the clinical presentations and response to erythro-
mycin treatment, and found that 27% of the DPB patients
experienced recurrence of symptoms 20 months after
treatment, two-thirds of whom clinically improved after
the second course of erythromycin treatment. To the best
of our knowledge, this is the first study to report on the
management of recurrence of DPB.
Most epidemiological studies on DPB have come from
Japan. In Japan, patients with DPB are predominantly men
(approximately 58e67%) and nonsmokers (approximately
66%). Similarly, in this study, 52% of the patients were men
and 78% were nonsmokers. The clinical presentations
including age, chronic sinusitis history, chronic productive
cough, and crackling sounds while breathing were also
similar between Taiwanese and Japanese patients. A few
case reports have mentioned hemoptysis or body weight
loss. In our cohort, 30% of the patients reported hemoptysis
and 19% had unexplained body weight loss. A delayed
diagnosis and misdiagnosis of DPB are common. In one case
series from Hong Kong, the time from onset of symptoms to
diagnosis ranged from 1 year to 4 years.6 Another case se-
ries from China reported that 95.6% of their patients had
been misdiagnosed with other diseases such as chronic
bronchitis (44%), pulmonary tuberculosis (28%), and asthma
(5%).21 In our cohort, the interval between onset of symp-
toms and diagnosis was 4.3  4.2 years, and 81% of the
patients were misdiagnosed and initially treated for chronic
obstructive pulmonary disease or asthma. The high misdi-
agnosis rate and delayed diagnosis suggest that most clin-
ical physicians are not familiar with DPB and highlight the
importance of testing for DPB in patients with chronic
productive cough and chronic sinusitis and with a poor
response to chronic obstructive pulmonary disease or
asthma therapy.
Figure 2 Changes in lung function in the diffuse panbronchiolitis patients after erythromycin treatment. FVC and FEV1 were
significantly improved whereas there were no significant differences in changes of FEV1/FVC and FEF25e75% after erythromycin
treatment. FEF25e75% Z forced inspiratory flow at 25e75% of the pulmonary volume; FEF Z forced expiratory flow;
FEV1 Z forced expiratory volume in 1 second; FVC Z forced vital capacity.
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and definite cases should fulfill the first three criteria and
at least two of the remaining criteria.18 Our study is the
first to report the percentages of patients fulfilling each
criterion (Table 2). Although all of the patients had bilat-
eral, diffuse, small nodular shadows in radiological images,
only 72% of the patients had centrilobular micronodules on
chest CT, and only 30% of the patients showed an obstruc-
tive pattern in pulmonary function tests and
PaO2 < 80 mmHg. An increased CHA titer has been reported
in most Japanese patients,22,23 whereas it has been re-
ported to be almost negative in Chinese patients.24 In our
cohort, 78% of the patients had a CHA titer of  64. The
percentages of patients who fulfilled the criteria of typical
chest CT findings, hypoxemia, and positive CHA seemed to
be lower in Taiwanese patients than in Japanese patients,
possibly due to ethnic differences.Table 4 Clinical courses of diffuse panbronchiolitis
patients who experienced recurrence after erythromycin
treatment (n Z 6).
Value
Male 5 (83)
Duration of first erythromycin
treatment course (mo)
7.5  8.6
Disease-free interval (mo) 19.9  12.7
Duration of second erythromycin
treatment course (mo)
7.4  7.4
Clinical improvement after second
course of erythromycin treatment
4 (67)
Values given as mean  standard deviation or n (%).DPB affects the small airways, and FEF25e75% in
spirometry is thought to be sensitive in detecting small
airway obstruction. In this study, 64% of the patients had
FEV1/FVC < 70% and 88% had FEF25e75% < 65% of the
predicted value. FEF25e75% therefore seems to be more
sensitive than FEV1/FVC in diagnosing DPB. However, a
significant improvement in FEV1/FVC was found after
erythromycin treatment with no significant improvement in
FEF25e75% in this study. Further studies are needed to
evaluate the value of FEF25e75% in patients with DPB.
Based on clinical experience, erythromycin is identified
as the drug of choice for the treatment of DPB. Many
studies from Japan have established the efficacy of eryth-
romycin therapy in improving symptoms, lung function, CT
scan changes, and survival rate.25,26 In this study, 81.5% of
the patients experienced symptom relief following eryth-
romycin treatment; however, only 55.6% of the patients
achieved radiological improvement after erythromycin
treatment. A review article by Azuma and Kudoh27 in 2006
demonstrated a significant improvement in vital capacity
(before vs. after, 63.4  18.1% of predicted vs.
82.3  19.4% of predicted) and FEV1 (before vs. after,
60.5  11.6% of predicted vs. 65.7  12.0% of predicted)
after erythromycin treatment, which is consistent with our
findings (Figure 2).
Previous studies have shown the presence of numerous
neutrophils in the bronchoalveolar lavage fluid (BALF) of
DPB patients, associated with high concentrations of
interleukin-8 (IL-8). This suggested that the accumulation
of neutrophils and IL-8 in the airway lumen may play an
important role in the pathogenesis of the disease.28,29 It has
been documented that erythromycin treatment is associ-
ated with a reduction in absolute count and percentage of
neutrophils in the BALF of patients with DPB.30 Putting
Table 5 Literatures of diffuse panbronchiolitis in Taiwan.
Source Year Case
numbers
Gender Age FEV1/FVC
ratio
Treatment Treatment
duration (mo)
CHA
titer 64
Lung
biopsy
Tsai9 1991 2 M 31 N/A Erythromycin N/A N/A Yes
F 42 N/A Erythromycin N/A N/A Yes
Chu et al10 1992 1 M 33 26.0 Erythromycin N/A N/A Yes
Liao et al11 2001 1 M 43 58.0 Erythromycin 6 N/A Yes
Liao et al12 2006 1 M 70 83.2 Erythromycin 3 No No
Shih et al13 2006 1 M 29 N/A Erythromycin N/A N/A No
Wu et al14 2009 1 M 73 68.0 Clarithromycin N/A N/A No
Chai et al15 2010 1 F 45 73.4 Clarithromycin 6 No No
Lin and Liao16 2012 1 M 63 N/A Erythromycin 6 N/A No
This work 2015 27 M/F Z 1.08 56.6  18.5 66.7  13.1 Erythromycin 7.9  7.7 21/27 2/27
CHA Z cold hemagglutinin; FEV1 Z forced expiratory volume in one second; FVC Z forced vital capacity; N/A Z not available.
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tential makers to evaluate the efficacy of erythromycin and
treatment duration. Further research is warranted to
confirm this hypothesis.
According to current guidelines,20,31 the treatment
duration should range from 6 months to 2 years, however,
the precise duration of treatment remains unclear. A
reasonable point at which therapy can be terminated is
after the resolution of the symptoms and the disappearance
of centrilobular nodules on HRCT scans.32 Once treatment
has finished, the patient must be followed up for relapse of
symptoms and HRCT, as recurrence has been documented
even after lung transplantation.33
Of note, six of our patients experienced recurrence of
symptoms after stopping erythromycin treatment, and the
mean treatment duration was 7.5  8.6 months. Four of
these patients took erythromycin for < 6 months and their
average disease-free interval was 23.2 months. The
remaining two patients took erythromycin for > 1 year and
their average disease-free interval was 13.3 months.
Further investigations are necessary to clarify the rela-
tionship between treatment duration and recurrence rate.
Moreover, five males (83%) experienced recurrence, which
implies that male gender could be a risk factor for recur-
rence. However, a larger sample size is necessary to prove
this hypothesis. Although DPB has been widely studied for
over 50 years, few studies have focused on recurrence. We
hope that the current case can elicit interest and prompt
further research on this issue.
There are several limitations to this study. First, we
assumed that all of the DPB patients in our hospital
received a CHA test, and thus we defined DPB patients as
those who had received a CHA test. This assumption may
have caused underestimation of the case number because
not every physician considers CHA titer as a diagnostic tool
for DPB. Considering that DPB is a rare disease and that
there is no International Classification of Diseases, Ninth
Revision, Clinical Modification code for DPB, our method
may be the most practical way of enrolling patients retro-
spectively. In addition, this was a retrospective study using
existing data that were recorded for reasons other than
research. Some documentation was incomplete, and this
may have affected the statistical analysis. However, this
study is the first and largest cohort study of DPB in Taiwan,and it may serve as a pilot study for future perspective
studies.
We reported the clinical presentation and treatment
outcomes of Taiwanese DPB patients. Compared with Jap-
anese patients, fewer patients in this study had an elevated
CHA titer, obstructive ventilator impairment, and hypox-
emia. Overall, 27% of our DPB patients experienced a
relapse after completing the first course of erythromycin
treatment, most of whom were male. Two thirds of the
patients who relapsed had a good response to a second
course of erythromycin treatment. Further studies are
needed to investigate the risk factors of recurrent DPB,
such as the duration of erythromycin treatment and gender.
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